Reuters logo
BRIEF-Meridian bioscience comments on preliminary fiscal 2017 operating results
October 19, 2017 / 11:57 AM / a month ago

BRIEF-Meridian bioscience comments on preliminary fiscal 2017 operating results

Oct 19 (Reuters) - Meridian Bioscience Inc

* Meridian Bioscience Inc comments on preliminary fiscal 2017 operating results and provides fiscal 2018 revenue and earnings guidance

* Sees FY 2018 GAAP earnings per share $0.59 to $0.62

* Sees FY 2017 GAAP earnings per share $0.50 to $0.51

* Sees FY 2018 revenue up 3 to 6 percent

* Sees FY 2018 revenue $207 million to $212 million

* Sees FY 2017 revenue about $200.5 million

* Sees FY 2018 non-GAAP earnings per share $0.65 to $0.68

* FY2018 earnings per share view $0.68, revenue view $202.4 million -- Thomson Reuters I/B/E/S

* FY2017 earnings per share view $0.67, revenue view $198.4 million -- Thomson Reuters I/B/E/S

* Meridian Bioscience Inc - expect ‍C.difficile Toxins A/B & GDH test to launch in late fiscal 2018​

* Meridian - ‍expect to complete development on H.pylori/Clarithromycin resistance assay during fiscal 2018, enter clinical trials in early 2019​

* Meridian Bioscience Inc - ‍expect to launch illumigene CMV late in fiscal 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below